Aronson Jeffrey K
British Pharmacological Society, Green Templeton College, Woodstock Road, Oxford OX2 6HG, UK.
Br J Clin Pharmacol. 2012 Jun;73(6):843-5. doi: 10.1111/j.1365-2125.2012.04233.x.
At a James Black Conference held in Oxford on 20-22 June 2011, a group of senior clinical pharmacologists and their junior colleagues, other medical specialists, and pharmacists discussed an agenda for UK clinical pharmacology for the next 5 years, addressing the following broad questions. How should UK clinical pharmacology be further developed and delivered as a discipline in universities, the NHS, pharmaceutical companies, and regulatory authorities? How should teaching and training in UK clinical pharmacology and therapeutics be delivered and assessed? What topics should be priorities for research in UK academic clinical pharmacology? How should clinical pharmacology contribute to UK drugs policy? How should pharmacology and clinical pharmacology be further integrated, to the benefit of both? Numerous recommendations emerged, under the collective acronym VOICE, standing for Visibility, Outreach, Integration, Coverage and Emissaries. VISIBILITY: The visibility of the discipline needs to be increased. This could be done, for example, by increased activities in acute general medicine/toxicology, through activities of Medicines and Therapeutics Committees, participation in grand rounds, teaching and training, and monitoring therapeutic interventions, and by offering bolt-on training for other specialists (for example, short courses, MSc courses, and training programmes). OUTREACH: Methods of increasing outreach include roadshows in schools/medical schools, national special study modules, public education, press coverage, and social marketing. INTEGRATION: Closer collaborations with pharmacologists, clinical pharmacists, other prescribers, and pharmaceutical companies (e.g. through joint training programmes) are desirable. COVERAGE: Attention to neglected areas, such as general practice, paediatrics, obstetrics, geriatrics, anaesthetics, cancer, and immunology. EMISSARIES: Trainees to spread the word.
2011年6月20日至22日在牛津举行的一次詹姆斯·布莱克会议上,一群资深临床药理学家及其初级同事、其他医学专家和药剂师讨论了英国未来5年临床药理学的议程,探讨了以下广泛问题。作为一门学科,英国临床药理学应如何在大学、国民保健服务体系(NHS)、制药公司和监管机构中进一步发展并提供相关服务?英国临床药理学与治疗学的教学与培训应如何开展及评估?英国学术临床药理学研究的优先主题应该有哪些?临床药理学应如何为英国的药物政策做出贡献?药理学与临床药理学应如何进一步整合,以实现互利?会议提出了众多建议,这些建议共用首字母缩写VOICE来代表,分别是可见度(Visibility)、推广(Outreach)、整合(Integration)、覆盖范围(Coverage)和使者(Emissaries)。可见度:该学科的可见度需要提高。例如,可以通过在急性普通医学/毒理学方面增加活动、通过药物与治疗委员会的活动、参与大查房、教学与培训以及监测治疗干预措施来实现,还可以为其他专科医生提供附加培训(例如短期课程、硕士课程和培训项目)。推广:增加推广的方法包括在学校/医学院举办巡回展示、开展全国性特殊研究模块、进行公众教育、媒体报道以及社会营销。整合:与药理学家、临床药剂师、其他开处方者以及制药公司进行更紧密的合作(例如通过联合培训项目)是可取的。覆盖范围:关注被忽视的领域,如全科医疗、儿科、产科、老年医学、麻醉学、癌症和免疫学。使者:培训人员来传播相关信息。